Acorda Therapeutics Reports Second Quarter 2009 Financial Results.
Business Wire › August 04, 2009
Linked as:
Extract
Acorda Therapeutics Reports Second Quarter 2009 Financial Results.
* Acorda and Biogen Idec Agree to Fampridine-SR Ex-U.S. Collaboration on June 30, 2009
* Upfront Payment of $110 Million; Potential Deal Value Over $500 Million * Company Notified by U.S. Food and Drug Administration (FDA) that Advisory Committee Meeting Will be Held for Fampridine-SR HAWTHORNE, N.Y. -- Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced its financial results for the second quarter of 2009. "A very productive second quarter was highlighted by the completion of our ex-U.S. collaboration with Biogen Idec, which we believe could benefit pe...See the full content of this document
Sponsored links
